Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Jong W. Kwon"'
Publikováno v:
Biopharmaceutics & Drug Disposition. 27:147-156
The pharmacokinetic parameters of DA-7867 were compared after intravenous and oral administration at a dose of 10 mg/kg in control rats and in rats with water deprivation for 72 h (rat model of dehydration). After intravenous administration in the ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa82f9ab628ca381e07ad7a7afc9fab
https://doi.org/10.1002/bdd.496
https://doi.org/10.1002/bdd.496
Autor:
Hyun Hee Kwak, Han K. Chung, Seul Min Choi, Joo H. Lee, Myung Gyoon Lee, Jong W. Kwon, Jong O. Kim, Moohi Yoo, Jung H. Kim
Publikováno v:
Biopharmaceutics & Drug Disposition. 27:141-145
It was reported that gastric motility was delayed and gastric acid secretion was reduced in vagotomized dogs which mimics a low gastric acidity in humans. A delay in gastric motility causes long residence of amlodipine in the stomach. More unionized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836882632f81c2e7a0b1d2bb9366e15e
https://doi.org/10.1002/bdd.495
https://doi.org/10.1002/bdd.495
Publikováno v:
Biopharmaceutics & Drug Disposition. 27:125-131
A pharmacokinetic interaction between oral DA-8159 and amlodipine was evaluated in male Sprague–Dawley rats. In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC0−6 h of amlodipine was significantly greater than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8def19c5b09f9245748cd4032e28acca
https://doi.org/10.1002/bdd.491
https://doi.org/10.1002/bdd.491
Publikováno v:
European Journal of Pharmaceutical Sciences. 25:337-345
Effects of diabetes mellitus induced by streptozotocin (DMIS) on the pharmacokinetics of DA-7867 were investigated after i.v. and oral administration (10mg/kg) to control Sprague-Dawley rats and DMIS rats (at 7th and 29th days after administration of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3edbf50891b24b9131e5c91a3c290ca
https://doi.org/10.1016/j.ejps.2005.03.009
https://doi.org/10.1016/j.ejps.2005.03.009
Publikováno v:
International Journal of Pharmaceutics. 296:94-102
Little is known about chronopharmacokinetics of PDE V inhibitors in rats as well as in humans. Hence, the pharmacokinetics of DA-8159 and one of its metabolites, DA-8164, were investigated after intravenous and oral administration of DA-8159 at a dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f20e44df9bb17cd1a11b6eeab5d2791
https://doi.org/10.1016/j.ijpharm.2005.03.006
https://doi.org/10.1016/j.ijpharm.2005.03.006
Publikováno v:
Biopharmaceutics & Drug Disposition. 26:233-241
In order to find what types of hepatic microsomal cytochrome P450 (CYP) isozymes are involved in the metabolism of DA-8159 and in the formation of DA-8164 in rats, enzyme inducers, such as dexamethasone, phenobarbital, 3-methylcholanthrene and isonia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f7bd7097bedd530c67d72d2b1ef623e
https://doi.org/10.1002/bdd.453
https://doi.org/10.1002/bdd.453
Publikováno v:
Biopharmaceutics & Drug Disposition. 27:29-37
The pharmacokinetic parameters of DA-7867 were compared after intravenous and oral administration at a dose of 10 mg/kg to control rats and rats with acute renal failure induced by uranyl nitrate (rats with U-ARF). After intravenous administration in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3036038857df448f7e3e5f8734654c2e
https://doi.org/10.1002/bdd.478
https://doi.org/10.1002/bdd.478
Autor:
Yoon Gyoon Kim, Yu C. Kim, Hyun J. Shim, Myung Gull Lee, Won B. Kim, Jong W. Kwon, Joo H. Lee, So H. Kim
Publikováno v:
Biopharmaceutics & Drug Disposition. 26:269-277
Time-averaged total body clearance (Cl) and apparent volume of distribution at steady state (V(SS)) of DA-8159 after intravenous administration to mice (30 mg/kg), rats (30 mg/kg), rabbits (30 mg/kg) and dogs (3 mg/kg) were analysed as a function of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5df4b6fa381bdc7db20403c8e9730792
https://doi.org/10.1002/bdd.455
https://doi.org/10.1002/bdd.455
Publikováno v:
Biopharmaceutics & Drug Disposition. 26:173-182
After intravenous (at doses of 1, 2, 5, and 10 mg/kg) and oral (at doses of 1, 5, and 10 mg/kg) administration of torasemide, the pharmacokinetic parameters were dose-independent. Hence, the extent of absolute oral bioavailability (F) was also indepe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b62b7c685d8d98dccb04e52839cd69
https://doi.org/10.1002/bdd.447
https://doi.org/10.1002/bdd.447
Autor:
Suk-J. Chung, Jong W. Kwon, Ae K. Lee, Chang-K. Shim, Sang G. Kim, Inchul Lee, Soo K. Bae, Dae Y. Lee, Myung Gyoon Lee
Publikováno v:
Journal of Pharmaceutical Sciences. 93:2388-2398
Effects of cysteine on the pharmacokinetics of torasemide were investigated after intravenous administration at a dose of 2 mg/kg to control rats and rats with PCM and PCMC. Torasemide was reported to be mainly metabolized via hepatic CYP2C9 in human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aafac58ffecef5603741b85dce4237e7
https://doi.org/10.1002/jps.20151
https://doi.org/10.1002/jps.20151